About the Company
Peter H. Diamandis ( DEE-ə-MAN-diss; born May 20, 1961) is an American marketer, engineer, physician, and entrepreneur of Greek-American ethnicity. He is best known for being founder and chairman of the X Prize Foundation, cofounder and executive chairman of Singularity University and coauthor of The New York Times bestsellers Abundance: The Future Is Better Than You Think, The Future is Faster than You Think, How Converging Technologies Are Transforming Business, Industries, and Our Lives and BOLD: How to Go Big, Create Wealth, and Impact the World. He is former CEO and cofounder of the Zero Gravity Corporation, cofounder and vice chairman of Space Adventures Ltd., founder and chairman of the Rocket Racing League, cofounder of the International Space University, cofounder of Planetary Resources, cofounder of Celularity, founder of Students for the Exploration and Development of Space, vice chairman and cofounder of Human Longevity, Inc.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CELU News
Celularity Inc. to Host Investor and Analyst Research & Development Day
Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it ...
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and ...
Celularity Inc. (CELU)
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies ...
Celularity Inc. Class A
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and ...
Celularity Inc Ordinary Shares - Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Celularity Inc. (CELU)
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies ...
Celularity Inc - Ordinary Shares - Class A
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and ...
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse ...
Celularity Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...